Roth Remains Positive on Celldex (CLDX) Following RINTEGA Phase 2 Update
Tweet Send to a Friend
Roth Capital affirms Celldex Therapeutics, Inc. (NASDAQ: CLDX) with a Focus Pick rating and price target of $39 after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
